Tumor Fibroblast Growth Factor Receptor 4 Level Predicts the Efficacy of Lenvatinib in Patients With Advanced Hepatocellular Carcinoma - Concepedia

Concepedia

Publication | Open Access

Tumor Fibroblast Growth Factor Receptor 4 Level Predicts the Efficacy of Lenvatinib in Patients With Advanced Hepatocellular Carcinoma

DOI Full Paper Access

55

Citations

26

References

2020

Year

Masami Yamauchi, Atsushi Ono, Akira Ishikawa, Kenichiro Kodama, Shinsuke Uchikawa, Haruna Hatooka, Peiyi Zhang, Yuji Teraoka, Kei Morio, Hatsue Fujino,

Clinical and Translational Gastroenterology

Abstract

The tumor FGFR4 level was an independent predictor of response to lenvatinib.

References

	Year	Citations
Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles Aravind Subramanian, Pablo Tamayo, Vamsi K. Mootha, Proceedings of the National Academy of Sciences GeneticsGenomicsGene RecognitionBioinformatics DatabaseGene Expression Profiling	2005	54.5K
Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-years for 32 Cancer Groups, 1990 to 2015 Christina Fitzmaurice, Christine A. Allen, Ryan M Barber, JAMA Oncology	2016	6.2K
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial Masatoshi Kudo, Richard S. Finn, Shukui Qin, The Lancet HepatologyMedicineRandomised Phase 3Clinical TrialsPathology	2018	5.3K
Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection†‡ Richard K. Sterling, Eduardo Lissen, Nathan Clumeck, Hepatology	2006	4.6K
Comprehensive and Integrative Genomic Characterization of Hepatocellular Carcinoma Adrian Ally, Miruna Balasundaram, Rebecca Carlsen, Cell	2017	2.5K
Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma Ghassan K. Abou‐Alfa, Tim Meyer, Ann‐Lii Cheng, New England Journal of Medicine	2018	2.3K
Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets Kornelius Schulze, Sandrine Imbeaud, Éric Letouzé, Nature Genetics Potential Therapeutic TargetsExome SequencingMedicinePathologyCancer Genomics	2015	1.8K
Integrative Transcriptome Analysis Reveals Common Molecular Subclasses of Human Hepatocellular Carcinoma Yujin Hoshida, Sebastian Nijman, Masahiro Kobayashi, Cancer Research EngineeringHuman Hepatocellular CarcinomaPathologyTumor BiologyViral Hepatitis	2009	1.2K
Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial Andrew X. Zhu, Joon Oh Park, Baek‐Yeol Ryoo, The Lancet Oncology OncologyHepatologyClinical TrialsRamucirumab Versus PlaceboPharmacotherapy	2015	829
Whole-genome mutational landscape and characterization of noncoding and structural mutations in liver cancer Akihiro Fujimoto, Mayuko Furuta, Yasushi Totoki, Nature Genetics Whole-genome Mutational LandscapeSomatic VariantTumor HeterogeneityMedicineGenetics	2016	703

Page 1